
AI Revolution: Digital Biology with insitro's Daphne Koller
About this episode
Daphne Koller is the founder and CEO of insitro, a company using AI and machine learning to engineer drug discovery. In this conversation with a16z's Vijay Pande, she discusses how an LLM for cells could revolutionize drug discovery and how to bridge the technological and cultural divide between building with atoms and building with bits.
- [0:59] Why life sciences?
- [3:42] AI in the life sciences
- [7:20] LLM for cells
- [11:55] Engineering disease and drug discovery
- [13:51] Bits vs. atoms
- [17:55] The opportunity ahead
This conversation is part of our AI Revolution series, recorded August 2023 at a live event in San Francisco. The series features some of the most impactful builders in the field of AI discussing and debating where we are, where we’re going, and the big open questions in AI. Find more content from our AI Revolution series on www.a16z.com/AIRevolution.
Get every episode summarized
Each time a16z Live publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from a16z Live

How Startups are Fixing Healthcare Friction
a16z Live

What Comes After Mobile? Meta’s Andrew Bosworth on AI and Consumer Tech
a16z Live

Who Will Own the Internet? a16z’s Chris Dixon on AI and Crypto
a16z Live

How AI Is Changing Warfare, with Anduril CEO Brian Schimpf
a16z Live